Regeneron, Bayer report positive Phase III results for DME treatment
August 12th 2013Regeneron Pharmaceuticals and Bayer HealthCare have announced that in the Phase III trials of Eylea (aflibercept) injection for treating DME, Eylea 2 mg achieved significantly greater improvement in BCVA from baseline compared with laser photocoagulation at 52 weeks.
New Partnership Endowment will fund grants to schools, colleges of optometry
August 12th 2013An agreement establishing a new Partnership Endowment was signed recently at the board of directors’ meeting of the Partnership Foundation for Optometric Education and the Association of Schools and Colleges of Optometry.
The Sunshine Act: What it means to you, what you need to do
August 6th 2013The Physician Payments Sunshine Act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to members of the health care community.